Clinuvel Pharmaceuticals Limited (CLVLF)
OTHER OTC:CLVLF
CLVLF Stock Chart & Stats
$7.23
-$0.52(-6.64%)
At close: 4:00 PM EST
$7.23
-$0.52(-6.64%)
Day’s Range― - ―
52-Week Range$5.98 - $8.93
Previous CloseN/A
Volume151.00
Average Volume (3M)121.00
Market Cap
$342.18M
Enterprise Value$461.02M
Total Cash (Recent Filing)$233.00M
Total Debt (Recent Filing)$341.09K
Price to Earnings (P/E)15.0
Beta0.33
Next Earnings
Sep 01, 2026EPS Estimate
0.36Next Dividend Ex-DateN/A
Dividend Yield0.42%
Share Statistics
EPS (TTM)0.14
Shares Outstanding50,200,740
10 Day Avg. Volume205
30 Day Avg. Volume121
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.16
Price to Sales (P/S)5.47
P/FCF Ratio12.74
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue4.79
Enterprise Value/Gross Profit7.51
Enterprise Value/Ebitda11.07
Forecast
1Y Price Target
$14.44Price Target Upside99.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.5
Revenue Forecast (FY)$70.31M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthClinuvel's minimal leverage and prolonged debt-free status provide durable financial flexibility, lowering refinancing risk and enabling funded development. A strong equity ratio and high ROE support investment in R&D and commercialization without urgent external financing needs.
Sustained ProfitabilityTwenty consecutive profitable periods and healthy margins indicate durable pricing power and disciplined cost control in a niche specialty market. Continued profitability reduces dilution risk, supports ongoing reinvestment in clinical programs, and underpins stable operational funding.
Cash Generation & LiquidityLarge cash reserves and consistent operating cash flow, supplemented by interest income from term deposits, create a multi-year runway to fund vitiligo and other programs. This strong liquidity profile reduces financing risk and enables controlled expansion and capex timing.
Bears Say
Slowing Revenue GrowthRevenue growth at mid-single-digit rates constrains the scalability of fixed-cost investments and limits organic expansion. In a small, specialized end market, modest top-line momentum increases reliance on new indications or geographies to materially lift long-term revenue trajectories.
Rising Operating ExpensesMaterial expense growth—across personnel, commercial distribution and R&D—risks compressing margins if revenue growth does not accelerate. Persistent expense expansion could erode free cash flow conversion and force reprioritization of programs or slower commercial rollouts.
Regulatory & Program Timing RiskThe requirement to finish multiple clinical programs before regulatory submissions, coupled with pending SEC feedback on ADR uplisting, introduces sequencing delays. These timing uncertainties can push out commercialization and revenue diversification, extending time to material returns.
Clinuvel Pharmaceuticals News
CLVLF FAQ
What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?
Clinuvel Pharmaceuticals Limited lowest stock price was $5.98 and its highest was $8.93 in the past 12 months.
What is Clinuvel Pharmaceuticals Limited’s market cap?
Clinuvel Pharmaceuticals Limited’s market cap is $342.18M.
When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?
Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Sep 01, 2026 which is in 156 days.
How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?
Clinuvel Pharmaceuticals Limited released its earnings results on Feb 25, 2026. The company reported $0.144 earnings per share for the quarter, missing the consensus estimate of $0.205 by -$0.061.
Is Clinuvel Pharmaceuticals Limited overvalued?
According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued.
Does Clinuvel Pharmaceuticals Limited pay dividends?
Clinuvel Pharmaceuticals Limited pays a Annually dividend of $0.033 which represents an annual dividend yield of 0.42%. See more information on Clinuvel Pharmaceuticals Limited dividends here
What is Clinuvel Pharmaceuticals Limited’s EPS estimate?
Clinuvel Pharmaceuticals Limited’s EPS estimate is 0.36.
How many shares outstanding does Clinuvel Pharmaceuticals Limited have?
Clinuvel Pharmaceuticals Limited has 50,200,740 shares outstanding.
What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?
Clinuvel Pharmaceuticals Limited reported an EPS of $0.144 in its last earnings report, missing expectations of $0.205. Following the earnings report the stock price went down -6.143%.
Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in CLVLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clinuvel Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.44 (99.72% Upside)
$14.44 (99.72% Upside)
Blogger Sentiment
Bullish
CLVLF Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.09%
12-Months-Change
Fundamentals
Return on Equity
13.29%
Trailing 12-Months
Asset Growth
22.98%
Trailing 12-Months
Company Description
Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
CLVLF Company Deck
CLVLF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a generally positive outlook driven by modest revenue growth, record first-half sales, strong cash reserves and sustained profitability while management deliberately invests in in-house R&D, clinical and manufacturing capabilities. Those positives are tempered by materially higher operating expenses across personnel, R&D and corporate areas, a non-cash FX translation loss, and timing/uncertainty around regulatory filings (CUV107 completion required before submission) and the NASDAQ ADR uplift. On balance, the company emphasizes that expense increases are strategic investments supported by a strong balance sheet and cash runway.View all CLVLF earnings summariesCLVLF Stock 12 Month Forecast
Average Price Target
$14.44
▲(99.72% Upside)
Technical Analysis
Opthea
―
Immutep Ltd
―
PYC Therapeutics Limited
―
Clarity Pharmaceuticals Ltd.
―
Botanix Pharmaceuticals Limited
―
Ownership Overview
―
Insiders
2.82% Mutual Funds
― Other Institutional Investors
95.44% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---